Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Roberts

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Orphanet Journal of Rare Diseases|August 26, 2017
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseBarry J Byrne, Tarekegn Geberhiwot, Bruce A Barshop, et al.
Journal of Neurology|June 19, 2024
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe RegistryKenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Oncotarget|October 4, 2017
BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligandsKimberly Mayes, Zeinab Elsayed, Aiman Alhazmi, et al.
Journal of Neurology|July 31, 2025
Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe RegistryKenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Journal of Patient-Reported Outcomes|November 13, 2024
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe diseasePriya S Kishnani, Barry J Byrne, Kristl G Claeys, et al.
Current Biology : CB|April 30, 2025
Genetic basis of an adaptive polymorphism controlling butterfly silver iridescenceLuca Livraghi, Joseph J Hanly, Ling S Loh, et al.
Neuromuscular Disorders : NMD|February 8, 2011
Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodiesHarriet P Lo, Enrico Bertini, Massimiliano Mirabella, et al.
Progress in Neurobiology|February 1, 2020
White matter structure and myelin-related gene expression alterations with experience in adult ratsCassandra Sampaio-Baptista, Astrid Vallès, Alexandre A Khrapitchev, et al.
The Lancet. Neurology|November 20, 2021
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trialBenedikt Schoser, Mark Roberts, Barry J Byrne, et al.
Muscle & Nerve|October 21, 2017
Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophyGermán Morís, Libby Wood, Roberto FernáNdez-Torrón, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Orphanet Journal of Rare Diseases|August 26, 2017
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseBarry J Byrne, Tarekegn Geberhiwot, Bruce A Barshop, et al.
Journal of Neurology|June 19, 2024
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe RegistryKenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Oncotarget|October 4, 2017
BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligandsKimberly Mayes, Zeinab Elsayed, Aiman Alhazmi, et al.
Journal of Neurology|July 31, 2025
Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe RegistryKenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Journal of Patient-Reported Outcomes|November 13, 2024
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe diseasePriya S Kishnani, Barry J Byrne, Kristl G Claeys, et al.
Current Biology : CB|April 30, 2025
Genetic basis of an adaptive polymorphism controlling butterfly silver iridescenceLuca Livraghi, Joseph J Hanly, Ling S Loh, et al.
Neuromuscular Disorders : NMD|February 8, 2011
Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodiesHarriet P Lo, Enrico Bertini, Massimiliano Mirabella, et al.
Progress in Neurobiology|February 1, 2020
White matter structure and myelin-related gene expression alterations with experience in adult ratsCassandra Sampaio-Baptista, Astrid Vallès, Alexandre A Khrapitchev, et al.
The Lancet. Neurology|November 20, 2021
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trialBenedikt Schoser, Mark Roberts, Barry J Byrne, et al.
Muscle & Nerve|October 21, 2017
Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophyGermán Morís, Libby Wood, Roberto FernáNdez-Torrón, et al.
Pageof 19